Tanaproget is primarily studied for its potential applications in the field of medicine, particularly in reproductive health. It is a selective progesterone receptor modulator (SPRM) that has shown promise in the treatment of conditions related to hormonal imbalances. Research has explored its use in managing endometriosis, a painful condition where tissue similar to the lining inside the uterus grows outside it. Additionally, it has been investigated for its role in contraception, offering a non-hormonal alternative to traditional birth control methods. Its ability to modulate progesterone receptors makes it a candidate for addressing uterine fibroids and other progesterone-dependent disorders. Ongoing studies aim to further validate its efficacy and safety in clinical settings.